News Palatin Technologies, Inc.

Equities

PTN

US6960775020

Market Closed - Nyse Other stock markets 04:00:00 2024-04-22 pm EDT			5-day change	1st Jan Change
1.72 ^USD	-6.52%		-5.49%	-56.78%

Apr. 08	Palatin Announces Phase 3 Pl9643 Melody-1 Dry Eye Disease Clinical Data Results Presented At American Society of Cataract and Refractive Surgery 2024	CI
Feb. 28	Sector Update: Health Care Stocks Decline Late Afternoon	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

PALATIN ANNOUNCES PHASE 3 PL9643 MELODY-1 DRY EYE DISEASE CLINICAL DATA RESULTS PRESENTED AT AMERICAN SOCIETY OF CATARACT AND REFRACTIVE SURGERY 2024	Apr. 09	AQ
Palatin Announces Phase 3 Pl9643 Melody-1 Dry Eye Disease Clinical Data Results Presented At American Society of Cataract and Refractive Surgery 2024	Apr. 08	CI
PALATIN ANNOUNCES RESULTS OF PL9643 MELODY-1 PIVOTAL PHASE 3 CLINICAL TRIAL IN PATIENTS WITH DRY EYE DISEASE	Feb. 29	AQ
Sector Update: Health Care Stocks Decline Late Afternoon	Feb. 28	MT
Palatin Shares Skid After Dry Eye Drug Candidate Misses Part of Targets in Late-Stage Trial	Feb. 28	MT
Transcript : Palatin Technologies, Inc. - Special Call	Feb. 28
Transcript : Palatin Technologies, Inc., Q2 2024 Operating Results Call, Feb 15, 2024	Feb. 15
Palatin Technologies, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	Feb. 14	CI
PALATIN ANNOUNCES DATABASE LOCK FOR PL9643 MELODY-1 PIVOTAL PHASE 3 CLINICAL TRIAL IN PATIENTS WITH DRY EYE DISEASE	Feb. 06	AQ
Palatin Announces Database Lock for PL9643 Melody-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease	Feb. 05	CI
PALATIN ANNOUNCES $10 MILLION REGISTERED DIRECT OFFERING	Jan. 31	AQ
PALATIN PROVIDES CORPORATE UPDATE AND HIGHLIGHTS STRATEGIC PRIORITIES FOR CALENDAR YEAR 2024	Jan. 09	AQ
Palatin Technologies, Inc. Provides Corporate Update and Highlights Strategic Priorities for Year 2024	Jan. 08	CI
Cosette Pharmaceuticals Acquires Vyleesi® (Bremelanotide Injection) from Palatin Technologies Inc.	Jan. 03	BU
Cosette Pharmaceuticals, Inc. acquired worldwide rights to Vyleesi from Palatin Technologies, Inc. for approximately $170 million.	Dec. 19	CI
Top Premarket Decliners	Dec. 15	MT
PALATIN REPORTS FIRST QUARTER FISCAL YEAR 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE	Nov. 15	AQ
Transcript : Palatin Technologies, Inc., Q1 2024 Earnings Call, Nov 14, 2023	Nov. 14
Palatin Technologies, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	Nov. 14	CI
PALATIN TO REPORT FIRST QUARTER FISCAL YEAR 2024 RESULTS, TELECONFERENCE AND WEBCAST TO BE HELD ON NOVEMBER 14, 2023	Nov. 10	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Palatin Technologies, Inc.

Equities

PTN

US6960775020

Summary

Filters